Sarepta Wins Full Approval and Label Expansion for DMD Gene Therapy 6/21/2024

A class of drugs already on the market to lower blood pressure appears to reduce adults' risk of developing epilepsy, Stanford Medicine researchers and their colleagues have discovered. The finding comes out of an analysis of the medical records of more than 2 million Americans taking blood pressure medications.

The study, published June 17 in JAMA Neurology, suggests that the drugs, called angiotensin receptor blockers, could prevent epilepsy in people at highest risk of the disease, including older adults who have had strokes.

Lilly Takes More Legal Actions Over Compounded Tirzepatide, Warns About Counterfeits 6/20/2024

Gilead’s Twice-Yearly Shot Shows 100% Efficacy in Phase III HIV Prevention Trial in Women 6/20/2024

PTC Reports Positive Phase II Huntington’s Data, FDA Lifts Partial Clinical Hold 6/20/2024

Challenging Research Models to Improve Health Equity 6/20/2024

Experimental Parkinson’s Treatment Elicits Antibodies Against Toxic Protein in Phase I 6/20/2024

BioSpace at #DIA2024: Workforce Trends, Trial Design, Peter Marks & Recap 6/20/2024

Executives Share Top Tips for a Successful Career Journey 6/20/2024

Better Collaboration: 7 Tips for Effective Workplace Communication 6/20/2024

FTC Supports PTO Push for Patent Settlement Scrutiny, Better Antitrust Oversight 6/20/2024

NIH Finds Non-Chemo Drug Combo Induces Lasting Remission in DLBCL Patients 6/20/2024

Prostate Drugs May Find New Use in Reducing Risk of Dementia: Study 6/20/2024

Tuberculosis is still one of the deadliest infectious diseases, causing over one million deaths each year worldwide. On the other hand, about one-fourth of the world's population carries Mycobacterium tuberculosis (M. tuberculosis) without showing any symptoms, and most of these carriers do not develop the disease.

The current anti-tuberculosis vaccine, BCG, is administered worldwide. However, considering that more than 10 million new tuberculosis cases are reported each year, its effectiveness is deemed insufficient.

Bayer announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China has granted Breakthrough Therapy designation for BAY 2927088, a potential new targeted therapy for adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC), whose tumors have activating HER2 (ERBB2) mutations, and who have received a prior systemic therapy. The CDE's designation for BAY 2927088 follows the Breakthrough Therapy designation granted by the U.S. Food and Drug Administration (FDA) in February 2024 for the same patient population.

BIOSECURE’s Surprise Absence, the $100+ Billion Future Weight-Loss Market, DIA and More 6/18/2024

Zentalis Hit With FDA Partial Clinical Hold on Cancer Studies After Patient Deaths 6/18/2024

AstraZeneca’s Truqap Flops in Phase III Triple-Negative Breast Cancer Trial 6/18/2024

Merck Wins FDA Approval for First Pneumococcal Vaccine Designed for Adults 6/18/2024

GSK Reignites Blenrep Blockbuster Aspirations With Data from Phase III Studies 6/18/2024